Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Core Insights - Kymera Therapeutics has initiated dosing in its BREADTH Phase 2b clinical trial for KT-621, targeting moderate to severe eosinophilic asthma, with data expected in late-2027 [1][2] - The company is also conducting the BROADEN2 Phase 2b trial for atopic dermatitis, with results anticipated by mid-2027 [1][3] - KT-621 is a first-in-class oral degrader of STAT6, aimed at treating Type 2 inflammatory diseases, showing promising results in earlier studies [4] Group 1: Clinical Trials - The BREADTH Phase 2b trial is a global, randomized, double-blind, placebo-controlled study involving approximately 264 adult patients over 12 weeks, focusing on the efficacy, safety, and tolerability of KT-621 [2] - The primary endpoint of the BREADTH trial is the change in forced expiratory volume in one second (FEV1) from baseline, with secondary endpoints assessing additional safety and quality of life measures [2] - The BROADEN2 trial is parallel to the BREADTH trial and is expected to accelerate the development of KT-621 for multiple Type 2 indications [3] Group 2: Product Information - KT-621 is designed to degrade STAT6, a key transcription factor in IL-4/IL-13 signaling, which drives Type 2 inflammation [4] - In Phase 1 studies, KT-621 demonstrated significant STAT6 degradation and reductions in Type 2 inflammatory biomarkers, along with improvements in clinical endpoints and patient-reported outcomes [4] - The drug has the potential to address a wide range of Type 2 diseases affecting over 140 million patients globally, including asthma and atopic dermatitis [4] Group 3: Industry Context - Asthma is a chronic inflammatory lung disease with significant unmet treatment needs despite existing therapies [5] - The ongoing development of KT-621 reflects the industry's focus on innovative oral treatments that can provide biologics-like efficacy for inflammatory diseases [4][6] - Kymera Therapeutics is positioned as a pioneer in targeted protein degradation, aiming to develop effective therapies for conditions that are difficult to treat with conventional methods [6][7]